As of today (2024-06-05), the Forward Annual Dividend Yield of Pyxis Oncology is 0.00%.
As of today (2024-06-05), the Trailing Annual Dividend Yield of Pyxis Oncology is 0.00%.
PYXS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.63 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Pyxis Oncology's Forward Dividend Yield %
For the Biotechnology subindustry, Pyxis Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Pyxis Oncology Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your